Search results

Page results

• Antibody levels vary according to vaccine type and previous infection with COVID-19

  Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.

• New study to evidence outcomes for marginalised children

  A new UCLH-hosted National Institute of Health and Care Research (NIHR) funded study will address health, education and social care outcomes for marginalised children and young people. This work will explore what works, what does not work, identify important gaps in practice, law and policy - and consider what we might do to address these.

• UCLH researchers first in the world to trial novel cancer treatment

  Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.

• Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease

  A large trial at UCLH and UCL will investigate whether a drug currently in use to treat respiratory conditions can slow the progress of Parkinson’s disease.

• Trained dogs identify Covid-19 with up to 94% accuracy

  People infected with coronavirus have a distinct odour that can be detected by trained dogs with a high degree of accuracy, according to new research involving UCLH.

• UCLH clinicians elected to Academy of Medical Sciences

  UCLH Director of Research Professor Bryan Williams and Consultant Neuropsychologist at UCLH Professor Lisa Cipolotti have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to biomedical and health science.

• Mild Covid-19 infection very unlikely to cause lasting heart damage

  Mild Covid-19 infection is very unlikely to cause lasting damage to the structure or function of the heart, according to a study supported by the NIHR UCLH Biomedical Research Centre and UCLH Charity.

• UCLH to lead data initiative to improve care for myeloma patients

  UCLH is to lead an initiative to improve care for myeloma patients alongside Oxford University Hospitals NHS Foundation Trust (OUH) and University Hospital Southampton NHS Foundation Trust (UHS).

• UCLH patient first in world to receive a new investigational drug in a phase 1 trial

  A UCLH patient with a rare hormonal condition is the first in the world to receive a new investigational drug in a first-in-human trial.

• Alternating vaccines trial to include two additional vaccines

  The Com-Cov trial in which UCLH is a site looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines.